We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you accept our Privacy Policy and Terms of Service, revised from time to time, and you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Atossa Genetics Inc. (ATOS - Free Report) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
Atossa Genetics Inc. is a member of our Medical group, which includes 1020 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Atossa Genetics Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ATOS' full-year earnings has moved 3.1% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the most recent data, ATOS has returned 11.4% so far this year. Meanwhile, stocks in the Medical group have lost about 5% on average. This shows that Atossa Genetics Inc. is outperforming its peers so far this year.
One other Medical stock that has outperformed the sector so far this year is Gilead Sciences (GILD - Free Report) . The stock is up 12.4% year-to-date.
For Gilead Sciences, the consensus EPS estimate for the current year has increased 15.4% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Atossa Genetics Inc. belongs to the Medical - Instruments industry, which includes 86 individual stocks and currently sits at #49 in the Zacks Industry Rank. On average, stocks in this group have gained 3% this year, meaning that ATOS is performing better in terms of year-to-date returns.
In contrast, Gilead Sciences falls under the Medical - Biomedical and Genetics industry. Currently, this industry has 501 stocks and is ranked #68. Since the beginning of the year, the industry has moved -13.1%.
Atossa Genetics Inc. and Gilead Sciences could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Atossa Genetics Inc. (ATOS - Free Report) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
Atossa Genetics Inc. is a member of our Medical group, which includes 1020 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Atossa Genetics Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ATOS' full-year earnings has moved 3.1% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the most recent data, ATOS has returned 11.4% so far this year. Meanwhile, stocks in the Medical group have lost about 5% on average. This shows that Atossa Genetics Inc. is outperforming its peers so far this year.
One other Medical stock that has outperformed the sector so far this year is Gilead Sciences (GILD - Free Report) . The stock is up 12.4% year-to-date.
For Gilead Sciences, the consensus EPS estimate for the current year has increased 15.4% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Atossa Genetics Inc. belongs to the Medical - Instruments industry, which includes 86 individual stocks and currently sits at #49 in the Zacks Industry Rank. On average, stocks in this group have gained 3% this year, meaning that ATOS is performing better in terms of year-to-date returns.
In contrast, Gilead Sciences falls under the Medical - Biomedical and Genetics industry. Currently, this industry has 501 stocks and is ranked #68. Since the beginning of the year, the industry has moved -13.1%.
Atossa Genetics Inc. and Gilead Sciences could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.